8-K: Health In Tech Secures $7M PIPE for Growth

Health In Tech, an AI-enabled InsurTech platform, announced a $7.0 million private placement of common stock to fund sales expansion and technology development.

Summary

• Health In Tech, Inc. (Nasdaq: HIT) entered into a Private Investment in Public Equity (PIPE) financing with certain accredited investors.
• The company will issue an aggregate of 5,600,000 shares of its common stock, par value $0.001 per share, at a price of $1.25 per share.
• The gross proceeds to the company from the PIPE are expected to be approximately $7.0 million, before deducting placement agent fees and estimated offering expenses.
• Net proceeds from the PIPE are intended to be used to expand sales distribution, advance technology development, support new product development, and for general corporate purposes and working capital.
• The transaction is expected to close on or about March 27, 2026, subject to the satisfaction of customary closing conditions.
• Craig-Hallum Capital Group LLC acted as the sole placement agent, receiving a cash placement fee of 6.0% of gross proceeds (plus an additional 1.0% for institutional investors) and reimbursement of certain out-of-pocket expenses, capped at $125,000 (excluding blue sky and FINRA filings).
• In connection with the PIPE, the company entered into a Registration Rights Agreement, committing to file a resale registration statement within 30 calendar days and use commercially reasonable efforts to have it declared effective within 45-75 calendar days.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as the company successfully secured capital to fund its growth strategies, albeit with some shareholder dilution and associated costs. The clear allocation of funds to key strategic areas is a positive sign for future development.

Positives

• Successfully secured approximately $7.0 million in gross proceeds, providing substantial capital for strategic initiatives.
• Funds are specifically allocated to key growth areas: expanding sales distribution, advancing technology development, and supporting new product development.
• The capital infusion is intended to strengthen the company's financial position for general corporate purposes and working capital.

Negatives

• The issuance of 5,600,000 new shares will result in dilution for existing shareholders.
• Placement agent fees (6.0% to 7.0% of gross proceeds) and other offering expenses will reduce the net proceeds available to the company.
• The company is subject to potential liquidated damages if it fails to meet the specified deadlines for filing and achieving effectiveness of the resale registration statement, which could be up to 6% of the Subscription Amount plus 1.5% interest per month.

Risks

• Failure to meet the deadlines for filing and effectiveness of the resale registration statement could trigger significant liquidated damages, potentially impacting the company's financial performance.
• The company's actual results, levels of activity, performance, or achievements may differ from forward-looking statements due to known and unknown risks, uncertainties, and other factors, as detailed in its Annual and Quarterly Reports on Form 10-K and 10-Q.
• During a 'Restricted Period' (until 60 days after the resale registration statement is effective), the company is prohibited from certain equity issuances, including 'Variable Rate Transactions,' which could limit future financing flexibility.
• The company cannot undertake a reverse or forward share split or reclassification of common stock for one year without purchaser consent, unless it is for maintaining the listing of shares on the Trading Market.

Future Outlook

The company intends to use the net proceeds from the PIPE to expand sales distribution, advance technology development, support new product development, and for general corporate purposes and working capital, aiming to strengthen its operational capabilities and market position within the AI-enabled InsurTech sector.

Management Comments

• Health In Tech, Inc. (Nasdaq: HIT), an AI-enabled InsurTech platform company, today announced that it has entered into a securities purchase agreement for a private investment in public equity financing (the PIPE) that is expected to result in gross proceeds of approximately $7.0 million before deducting placement agent fees and offering expenses.
• The Company intends to use the net proceeds from the PIPE to expand sales distribution, advance technology development, support new product development, and for general corporate purposes and working capital.

Industry Context

StockSavvy.ai notes that this capital raise positions Health In Tech to further invest in its AI-enabled InsurTech platform, a sector experiencing significant growth and innovation. The focus on sales distribution, technology, and new product development aligns with broader industry trends where digital transformation and data-driven solutions are critical for competitive advantage. This move could enable Health In Tech to better compete with established InsurTech players and traditional insurers adopting new technologies.

Comparison to Industry Standards

• The $1.25 per share price and $7.0 million raise size are specific to Health In Tech and cannot be directly compared to global benchmarks without more context on the company's valuation and market conditions.
• The placement agent fees (6-7%) are within the typical range for PIPE transactions, which can vary based on deal size, market conditions, and the complexity of the offering.
• The commitment to file a resale registration statement within 30 days and achieve effectiveness within 45-75 days is standard practice for PIPE deals to ensure liquidity for investors.

Stakeholder Impact

• Shareholders: Existing shareholders will experience dilution due to the issuance of 5,600,000 new shares. However, the capital raise provides funds for growth initiatives that could increase long-term shareholder value.
• Employees: The capital raise supports technology and new product development, potentially leading to new opportunities or stability within the company.
• Customers: Investment in technology and new products could lead to improved offerings and services.
• Creditors: The capital raise strengthens the company's financial position, potentially improving its ability to meet financial obligations.

Next Steps

• Closing of the PIPE transaction on or about March 27, 2026.
• Filing of a resale registration statement with the SEC within 30 calendar days of March 25, 2026.
• Using commercially reasonable efforts to have the resale registration statement declared effective within 45-75 calendar days of filing.
• Expanding sales distribution, advancing technology development, and supporting new product development using the net proceeds.
• Maintaining the listing of common stock on Nasdaq and ensuring eligibility for electronic transfer through the Depository Trust Company.

Key Dates

Recommendation

The capital raise provides necessary funding for Health In Tech's strategic growth initiatives, which is a positive. However, the significant dilution from the new share issuance and the associated costs warrant a cautious approach. While the funds are directed towards promising areas like AI-enabled technology and sales expansion, the execution risk and the immediate dilutive effect suggest a 'hold' position until further clarity on the impact of these investments on financial performance and market share is available.

Keywords

Health In Tech, HIT, PIPE, Private Placement, Equity Financing, Common Stock, InsurTech, AI-enabled platform, Capital Raise, Craig-Hallum Capital Group, SEC Filing, Form 8-K, Dilution, Registration Rights, Technology Development, Sales Distribution, New Product Development